Novavax Cash Flow Statement
NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
12.75+1.74 (+15.80%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Novavax free cash flow
In fiscal 2025, Novavax generated -$244.6 million of operating cash flow and spent $5.6 million on capital expenditures. That left free cash flow of -$250.2 million, a free-cash-flow margin of -22.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Novavax cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 440.30M | -187.50M | -545.06M | -657.94M | -1.74B | -418.26M | -132.69M | -184.75M | -183.77M | -279.97M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 28.00M | 48.00M | 41.00M | 29.00M | 13.00M | 4.30M | 5.10M | 7.40M | 7.60M | 7.70M |
| Stock-Based Compensation | 36.02M | 48.15M | 85.36M | 130.30M | 183.63M | 128.03M | 17.05M | 18.31M | 19.81M | 19.16M |
| Change in Working Capital | -887.71M | -22.22M | -376.84M | -361.15M | 1.73B | 12.02M | -24.02M | -21.14M | 3.33M | -8.70M |
| Operating Cash Flow | -244.63M | -87.26M | -713.97M | -415.94M | 322.95M | -42.54M | -136.62M | -184.82M | -144.48M | -258.77M |
| Capital Expenditures | -5.56M | -13.06M | -53.77M | -89.06M | -57.49M | -54.62M | -1.86M | -1.37M | -4.19M | -18.20M |
| Investing Cash Flow | -78.27M | -204.04M | -58.81M | -92.98M | 100.15M | -377.78M | 38.49M | 28.60M | 35.97M | 28.02M |
| Debt Issued | — | — | — | — | — | — | — | — | — | 315.00M |
| Financing Cash Flow | 27.74M | 260.58M | 4.47M | 324.99M | 461.71M | 984.76M | 98.38M | 102.81M | 64.54M | 279.85M |
| Net Change in Cash | -289.24M | -38.52M | -765.03M | -179.41M | 879.52M | 566.56M | 221.00K | -53.47M | -43.83M | 48.76M |
| Free Cash Flow | -250.19M | -100.32M | -767.74M | -504.99M | 265.46M | -97.16M | -138.48M | -186.20M | -148.66M | -276.97M |
This table shows 10 annual periods of Novavax's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NVAX's reporting calendar. What is a cash flow statement?